Sascha Alilovic

Salvia is a medical device company, active in the emerging field of “BioElectronics” that is inspired by biology and electronics to provide innovative therapeutic solutions. The name Salvia is derived from the Latin word salvere, which means "to stay healthy"​.​ We are driven to deliver bioelectronic solutions that restore health for people suffering from chronic migraine; our ambition is to make these novel therapies widely accessible. The Salvia team consists of experienced entrepreneurs, engineers and scientists with diverse professional backgrounds and proven track-record throughout the medical device industry (Sapiens, Medtronic, Philips, St Jude, BioSensors International, Kyphon, etc).

Neuro Event Labs develop scalable solutions for registering data about patient’s epilepsy seizures by using video and other sensors; combined with smart analytics helping medical staff to use the data efficiently; as well as tools for patients to take an active role in the care taking process. Neuro Event Labs started in 2015 as a spin-off of Intopalo.

GNA Biosolutions is a private molecular diagnostics company located in Germany. Our proprietary technology, Pulse Controlled Amplification (PCA), offers a novel, ultrafast, and cost-effective molecular diagnostic platform that captures and amplifies nucleic acids from complex clinical samples. PCA assays are being developed for a number of therapeutic areas, including infectious diseases and biothreats. Nucleic acid amplification is a fundamental process in molecular biology, with a multitude of applications. In collaboration with our partners around the world, our PCA technology is taking molecular testing to places it’s never been able to go before. Our vision is to bring the power of molecular testing, from sample to answer, to everyone, everywhere. For more information, please visit www.gna-bio.com

We develop and produce innovative medical devices for diagnostics purposes. We are on a mission to provide clinicians with predictive medical assessment, helping them discover diseases in the early stages and ensure all patients receive successful treatment. We are a trustworthy provider of digital and connected diagnostic devices for individual practices, hospitals, and home care globally. Our strong in-house research & development and a certified production facility help us instantly respond to the ever-changing requirements of healthcare. Our first innovation was a device used in diagnostics of peripheral arterial disease. This automated ankle-brachial pressure measuring device (MESI ABI MD) indicates occlusions of main arteries in lower extremities. The procedure takes only 3 minutes and it can be performed by a nurse, while the traditional procedure with hand doppler ultrasound takes much longer, and it requires a skilled operator to perform a measurement. In 2017 we introduced to the market MESI mTABLET designed with the modern healthcare practice in mind. The certified medical tablet integrates wireless diagnostic tools, patient records and medical apps in one system. The MESI mTABLET gives medical practitioners an option to use: - the first completely digital Electrogram, - flexible Pulse Oximeter, - wireless Blood Pressure, - fastest Ankle-Brachial Index, and - smartest Toe-Brachial Index measurement devices. The company is certified by ISO 13485. All developed medical devices are CE certified and assessed by customers as the most helpful and user-friendly in the medical field. All devices are MDR compliant. MESI mTABLET ABI, MESI mTABLET TBI and MESI mTABLET ECG are FDA-cleared as well.

PathoQuest helps biopharmaceutical developers and manufacturers get their therapies to market with our leading expertise in GMP NGS-based biosafety testing and characterization services. As innovator companies continue to bring exciting novel therapies to market, there is a critical need for alternative biosafety and characterization strategies. This is especially the case for life-changing cell and gene therapies, as well as novel viral vaccines. Classical testing approaches, such as cell based assays, are often challenging to implement due to high volume requirements, as well as compatibility issues. Biosafety testing and characterization are key regulatory requirements for the release of biologic therapies. Therefore, alternative methods which can address these issues are of intense interest. There is also a drive from across industry and regulators to reduce, and eventually eliminate the use of animal models used in biosafety testing. The genomic approach of Next Generation Sequencing (NGS) can solve many of the challenges that are faced by developers and manufacturers, such as lower volume requirements and incompatibility with cell-based assays From our origins within the Institut Pasteur, PathoQuest is leading the way in expertise for the provision of GMP NGS based biosafety testing. Our expertise is underlined with over 20 peer reviewed publications on NGS applications in biosafety testing; as well as active participation in industry groups such as PDA, ADVTIG, CAACB and EFPIA. PathoQuest are committed to bringing this game-changing genomic approach to biopharmaceutical developers and manufacturers. PathoQuest has a global footprint, with operations in Europe (Paris) and North America (Wayne, PA); and have provided NGS biosafety testing services to over 100 of the top biopharmaceutical companies globally. Why not get in touch to see how we can help you with your biosafety testing strategy?

Salvia is a medical device company, active in the emerging field of “BioElectronics” that is inspired by biology and electronics to provide innovative therapeutic solutions. The name Salvia is derived from the Latin word salvere, which means "to stay healthy"​.​ We are driven to deliver bioelectronic solutions that restore health for people suffering from chronic migraine; our ambition is to make these novel therapies widely accessible. The Salvia team consists of experienced entrepreneurs, engineers and scientists with diverse professional backgrounds and proven track-record throughout the medical device industry (Sapiens, Medtronic, Philips, St Jude, BioSensors International, Kyphon, etc).

Neuro Event Labs develop scalable solutions for registering data about patient’s epilepsy seizures by using video and other sensors; combined with smart analytics helping medical staff to use the data efficiently; as well as tools for patients to take an active role in the care taking process. Neuro Event Labs started in 2015 as a spin-off of Intopalo.

Tyromotion is one of the world´s leading manufacturers and suppliers of technology-based therapeutic devices with the goal to sustainably improve people's independence and quality of life. To accomplish this mission, Tyromotion has developed a pioneering therapy concept for the whole body, upper and lower extremities, during all phases of rehabilitation. Powerful new technologies, including robotics, sensor systems, virtual reality, and gamification, lead the patient through the continuum of care more intensively and motivationally. The sophisticated TyroS software is the heart of the Tyromotion platform and combines devices, clinical expertise, and therapeutic programs. The software provides a comprehensive patient view across all devices and fosters motor-learning principles, as well as task-oriented trainings. Coupled with numerous assessments and biofeedback, Tyromotion products facilitate several forms of rehabilitation for children and adults with various indications. The company, with headquarters in Graz, Austria, has additional offices in Germany and the USA and works with a global network of distribution partners.